Combination drug screen identifies synergistic drug interaction of BCL-XL and class I histone deacetylase inhibitors in MYC-amplified medulloblastoma cells
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
1 Online-Ressource.
- Language
-
Englisch
- Bibliographic citation
-
Combination drug screen identifies synergistic drug interaction of BCL-XL and class I histone deacetylase inhibitors in MYC-amplified medulloblastoma cells ; volume:166 ; number:1 ; day:7 ; month:1 ; year:2024 ; pages:99-112 ; date:1.2024
Journal of neuro-oncology ; 166, Heft 1 (7.1.2024), 99-112, 1.2024
- Creator
-
Zeuner, Simon
Vollmer, Johanna
Sigaud, Romain
Oppermann, Sina
Peterziel, Heike
ElHarouni, Dina
Oehme, Ina
Witt, Olaf
Milde, Till
Ecker, Jonas
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s11060-023-04526-w
- URN
-
urn:nbn:de:101:1-2024040911091797439303
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:58 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Zeuner, Simon
- Vollmer, Johanna
- Sigaud, Romain
- Oppermann, Sina
- Peterziel, Heike
- ElHarouni, Dina
- Oehme, Ina
- Witt, Olaf
- Milde, Till
- Ecker, Jonas
- SpringerLink (Online service)
Other Objects (12)
Targeting class I histone deacetylase 2 in MYC amplified group 3 medulloblastoma
Effective inhibition of MYC-amplified group 3 medulloblastoma by FACT-targeted curaxin drug CBL0137
Overcoming multiple drug resistance mechanisms in medulloblastoma
Overcoming multiple drug resistance mechanisms in medulloblastoma
Bcl-XL but Not Bcl-2 is a potential target in medulloblastoma therapy
Selective targeting of histone deacetylases in MYC amplified Group 3 medulloblastoma
The potential for histone deacetylase (HDAC) inhibitors as cestocidal drugs
A functional genomics approach to identify pathways of drug resistance in medulloblastoma
A high-throughput screening identifies histone deacetylase inhibitors as therapeutic agents against medulloblastoma
Class I HDAC inhibitor entinostat synergizes with PLK1 inhibitors in MYC-amplified medulloblastoma cells
Class I HDAC inhibition reduces DNA damage repair capacity of MYC-amplified medulloblastoma cells
Restoration of miR-193a expression is tumor-suppressive in MYC amplified Group 3 medulloblastoma
Targeting class I histone deacetylase 2 in MYC amplified group 3 medulloblastoma
Effective inhibition of MYC-amplified group 3 medulloblastoma by FACT-targeted curaxin drug CBL0137
Overcoming multiple drug resistance mechanisms in medulloblastoma
Overcoming multiple drug resistance mechanisms in medulloblastoma
Bcl-XL but Not Bcl-2 is a potential target in medulloblastoma therapy
Selective targeting of histone deacetylases in MYC amplified Group 3 medulloblastoma
The potential for histone deacetylase (HDAC) inhibitors as cestocidal drugs
A functional genomics approach to identify pathways of drug resistance in medulloblastoma
A high-throughput screening identifies histone deacetylase inhibitors as therapeutic agents against medulloblastoma
Class I HDAC inhibitor entinostat synergizes with PLK1 inhibitors in MYC-amplified medulloblastoma cells
Class I HDAC inhibition reduces DNA damage repair capacity of MYC-amplified medulloblastoma cells
Restoration of miR-193a expression is tumor-suppressive in MYC amplified Group 3 medulloblastoma
Targeting class I histone deacetylase 2 in MYC amplified group 3 medulloblastoma
Effective inhibition of MYC-amplified group 3 medulloblastoma by FACT-targeted curaxin drug CBL0137
Overcoming multiple drug resistance mechanisms in medulloblastoma
Overcoming multiple drug resistance mechanisms in medulloblastoma
Bcl-XL but Not Bcl-2 is a potential target in medulloblastoma therapy
Selective targeting of histone deacetylases in MYC amplified Group 3 medulloblastoma
The potential for histone deacetylase (HDAC) inhibitors as cestocidal drugs
A functional genomics approach to identify pathways of drug resistance in medulloblastoma
A high-throughput screening identifies histone deacetylase inhibitors as therapeutic agents against medulloblastoma
Class I HDAC inhibitor entinostat synergizes with PLK1 inhibitors in MYC-amplified medulloblastoma cells
Class I HDAC inhibition reduces DNA damage repair capacity of MYC-amplified medulloblastoma cells